Mallinckrodt Inc

Mallinckrodt — Debt Investor Presentation (August 2025)

57 slides from Mallinckrodt's debt investor presentation, Aug 1, 2025

  1. Slide 1: Par Health Transaction Overview

    Confidential and subject to change Par Health Confidential and subject to change Par Health Transaction Overview

  2. Slide 2: Transaction Summary

    Confidential and subject to change Par Health Confidential and subject to change Transaction Summary

  3. Slide 3: Transaction Summary

    Confidential and subject to change Par Health 1. PF. Adj. EBITDA burdened by $35mm of forecasted annual net dissynergies Transaction Summary 1 Sources New $200mm Revolver $ - New Unitranche Term Loan 1,150.0 Total Sources $1,150.0 MergeCo Transaction Uses $1,000.0 Cash to GxSI Balance Sheet 150.0 To

  4. Slide 4: Company Overview

    Confidential and subject to change Par Health Confidential and subject to change Company Overview

  5. Slide 5: Par Health Overview

    Confidential and subject to change Par Health Overview Par Health Reputation Combining two well known, reliable and reputable businesses Active Pharmaceutical Ingredients Premium products serving top-tier customers Sterile Injectables Critical medicines for hospitals Generic Pharmaceuticals High-qua

  6. Slide 6: Par Health market leader with robust product portfolio

    Confidential and subject to change Par Health ▪ Par Health’s combined Generics and Sterile Injectables is well positioned as a market leader with robust product portfolio spanning multiple disease areas, dosage forms and delivery technologies − Generics: ▪ Finished Dose Generics: A category leader a

  7. Slide 7: Seasoned Leadership Team

    Confidential and subject to change Seasoned Leadership Team Par Health Stephen Welch Chief Executive Officer 24 years at MNK Jack Boyle Chief Financial Officer Andrew Gonce Chief Operations Officer Jason Goodson Chief Strategy Officer Kass Harrold Chief Administrative Officer Jake Longenecker Chief

  8. Slide 8: Executive Summary

    Confidential and subject to change Par Health 1. Taken as pre-tax 2025E UFCF/ 2025E adj. EBITDA 2. EV/EBITDA multiple median includes Amneal, Amphastar, Ani, Organon, Sandoz, Teva and Viatris multiples as of 6/18/25 Executive Summary Creation of New GxSI (Generics + Sterile Injectables) Company Crea

  9. Slide 9: Business Segments Overview

    Confidential and subject to change Business Segments Overview Par Health Generics Sterile Injectables $1.1B 2025E Total Revenue (4.4%) Revenue CAGR (’25E–’27E) $273M 2025E Total Revenue 4.6% Revenue CAGR (’25E–’27E) $354M 2025E Total Revenue 7.5% Revenue CAGR (’25E–’27E) Finished Dose Generics ($1,0

  10. Slide 10: A) Generics Overview

    Confidential and subject to change Par Health Confidential and subject to change A) Generics Overview

  11. Slide 11: Finished Dose Generics | Overview

    Confidential and subject to change Finished Dose Generics | Overview Par Health Finished Dose Generics Revenue (’23A – ’27E) $1,103 $1,035 $1,104 $1,056 $985 $9 $36 $33 $1,103 $1,035 $1,113 $1,093 $1,018 2023A 2024A 2025E 2026E 2027E On-Market Pipeline Growth ▪ Portfolio of ~80 product families ▪ Pr

  12. Slide 12: Finished Dose Generics product table

    Confidential and subject to change Par Health Product: Branded Name % of 2025E Revenue Dosage Form Controlled Substance? Manufacturing (Vertically Integrated) Lidoderm AG LIDODERM® ~17% Topical patch API/FG: CMO Hydrocodone APAP Norco® ~13% Oral tablet C-II Vertically Integrated Dexlansoprazole DEXI

  13. Slide 13: Finished Dose Generics | Customer Relationships

    Confidential and subject to change Finished Dose Generics | Customer Relationships Par Health All Other and Government Sample Customers • CVS formularies • Omnicare • Cardinal • Target • Distributors, Optum • Regional chains • Walgreens • Cencora (AB) • Prime Therapeutics • Pharmerica • GPO with 4 m

  14. Slide 14: Active Pharmaceutical Ingredients | Overview

    Confidential and subject to change Par Health 1. For molecules we compete in Active Pharmaceutical Ingredients | Overview Active Pharmaceutical Ingredients (APIs) Revenue (’23A – ’27E) $324 $297 $273 $294 $299 2023A 2024A 2025E 2026E 2027E ▪ Only manufacturer of bulk acetaminophen in the Western Hem

  15. Slide 15: Active Pharmaceutical Ingredients | APAP Deep Dive

    Confidential and subject to change Active Pharmaceutical Ingredients | APAP Deep Dive Par Health Our Premium Products Serve The Upper Tier Of The Market, Resulting In Strong Relationships With Large, Blue-chip Customers Unique Position in Global Acetaminophen Market ▪ Fully owned, US-based manufactu

  16. Slide 16: APIs | Long-Term Customer Relationships

    Confidential and subject to change Par Health OTC Generics Active Pharmaceutical Ingredients | Long-Term Customer Relationships APAP Controlled Substances (CS) OTC Brands Selling to leading global customers across… Branded Generic Longstanding Relationships Across Blue-chip Market Leading Customers

  17. Slide 17: Market position and competitive intensity

    Confidential and subject to change Par Health Share of revenue by competitive intensity Percentage of portfolio, 2025 Net Revenues Finished Dose Gx Share of revenue by product family market position Percentage of portfolio, 2025 Net Revenues Finished Dose Gx 2% 8% 14% 76% 1 2 3-4 5+ 2025E Revenue $1

  18. Slide 18: SpecGx market leader in controlled substance families

    Confidential and subject to change Par Health Source: IQVIA 2024 Data, million extended Units 1. SpecGx LLC is the primary operating entity of Mallinckrodt’s generics business A Opioids (e.g., Gx Vicodin, Gx Percocet) ADHD (e.g., Gx Adderall, Gx Vyvanse) Addiction Treatment (e.g., Gx Suboxone, Naltr

  19. Slide 19: Generics | Growth Strategy

    Confidential and subject to change Par Health • API Business R&D focused on new Drug Master File (DMFs) to support the generics pipeline as well as enhanced API chemistries to increase yields and lower costs • St. Louis plant is largest API production facility in the country by volume with potential

  20. Slide 20: B) Sterile Injectables Overview

    Confidential and subject to change Par Health Confidential and subject to change B) Sterile Injectables Overview

  21. Slide 21: Sterile Injectables | Overview

    Confidential and subject to change Sterile Injectables | Overview Par Health Overview Financial Summary ▪ Diverse portfolio of 35+ life-enhancing products used in hospitals, health-systems and clinics ▪ Durable legacy products in both vial and RTU formats ▪ Domestic and low-cost capacity for interna

  22. Slide 22: Sterile Injectables Overview: Customers and Growth Strategy

    Confidential and subject to change Sterile Injectables Overview Par Health Key Customers Areas of Focus and Growth Strategy Hospitals 52% Clinics 32% Long Term Care 7% Other & Government 9% Hospitals • Acute care products in >95% of U.S. hospitals • Face-to-face key account management Clinics • Hosp

  23. Slide 23: Sterile Injectables | Product Portfolio

    Confidential and subject to change Par Health Product: % of 2025E Revenue Dosage Form Manufacturing (Vertically Integrated?) Market Share Adrenalin ~24% Injection Rochester (Vials / PFS) / CMO (Bags) 30% Aplisol ~19% Injection Rochester 47% Vasostrict ~10% Injection Rochester 52% Alvimopan Capsules

  24. Slide 24: Sterile Injectable Product Pipeline

    Confidential and subject to change Par Health Development Filed Refocused Pipeline Provides Meaningful Growth Opportunity Sterile Injectable Product Pipeline Pipeline data as of March 31, 2025 ~40 ~3 2025 planned launches PRODUCTS ~60% RTU and Differentiated Expect segment revenues to grow at a mid-

  25. Slide 25: C) Manufacturing and Quality Control

    Confidential and subject to change Par Health Confidential and subject to change C) Manufacturing and Quality Control

  26. Slide 26: Manufacturing Footprint

    Confidential and subject to change Manufacturing Footprint Par Health 10 Manufacturing Facilities 2 R&D Centers Capital investments include projects to enhance growth or increase efficiency as well as the requisite investments to maintain the site to ensure quality, regulatory and safety requirement

  27. Slide 27: Vertically Integrated Business

    Confidential and subject to change Par Health 10B+ Doses Capacity 1. Fenton, MO site leased in 2024, expected to be fully licensed for operation in 2025 Vertically Integrated Business ~10% APAP / COMPAP ~27,000 Metric Tons APAP Capacity Raleigh, NC APAP ~60% ~40% Greenville, IL COMPAP ~90% APAP to G

  28. Slide 28: Quality and Regulatory

    Confidential and subject to change Par Health 0 Warning letters or critical findings since 2020 Location Last FDA Inspection Observations St. Louis, MO Feb 2022 0 Raleigh, NC Jan 2019 0 Greenville, IL Jan 2019 1 Hobart, NY Jan 2025 4 Webster Groves, MO Sept 2023 2 Rochester, MI Jun 2025 1 Indore, In

  29. Slide 29: D) Additional Growth Levers

    Confidential and subject to change Par Health Confidential and subject to change D) Additional Growth Levers

  30. Slide 30: Additional growth levers

    Confidential and subject to change Par Health ▪ Favorable market dynamics, especially in sterile injectables and ADHD products, with strong demand driven in part by persistent industry supply challenges ▪ Commercial scale through integration enables greater go-to-market capabilities ▪ Multiple small

  31. Slide 31: Industry Overview and Outlook

    Confidential and subject to change Par Health Confidential and subject to change Industry Overview and Outlook

  32. Slide 32: Generics Market Overview

    Confidential and subject to change Generics Market Overview Par Health 1. Source: IQVIA, National Sales Perspectives and RxInsights, 2023 Note: Limited to Rx and OTC Insulins; Includes Retail, Non-Retail and Mail 2. Represents moving annual total for November 2023 3. Source: IQVIA, National Sales Pe

  33. Slide 33: Sterile Injectables Market Overview

    Confidential and subject to change Sterile Injectables Market Overview Par Health ~$200B Total Injectable Market Total Products 1,320 ~$150B Biologics Market BLA = 286 & Bio-similar = 16 ~$50B Small Molecule NDA = 513 & ANDA/AG = 375 ~$20B Retail/Mail ~$30B Non-Retail Areas of focus: • Specialty pha

  34. Slide 34: Macro backdrop and market dynamics

    Confidential and subject to change Par Health ▪ Combined business footprint unique with API, Gx, and SI capacity within US, supporting largest revenue area while minimizing tariff exposure (tariff risks exist on API starting materials, APAP exports, and Indian finished dose imports) ▪ Evolving legis

  35. Slide 35: Key Credit Highlights

    Confidential and subject to change Par Health Confidential and subject to change Key Credit Highlights

  36. Slide 36: Key Credit Highlights

    Confidential and subject to change Key Credit Highlights Par Health 2 Industry leading reputation for quality, compliance and service providing stability within existing and future regulatory frameworks 3 Robust pipelines in Sterile Injectables and core Generics support further growth and expand add

  37. Slide 37: Global Generics Business of Scale With a Robust Product Portfolio

    Confidential and subject to change Par Health Click to edit Master title style Par Health Can Address The Current And Everchanging Needs Of Today’s Patients And Prescribers Comprehensive portfolio of ~180 Products designed to meet a diverse array of patient needs Robust Portfolio A true market leade

  38. Slide 38: Suspicious Order Monitoring (SOM)

    Confidential and subject to change Par Health Suspicious Order Monitoring (SOM) What is it and why does it matter? Preventing the diversion of our controlled substances products is critical to our effortsto help ensure the legitimate medical needs of appropriate patients are met. Our Controlled Subs

  39. Slide 39: A Quality Culture of Excellence

    Confidential and subject to change Par Health ▪ A company-wide approach owned by senior leaders that empowers and engages all employees to: ✓ Embody company values and their associated behaviors ✓ Make risks, opportunities and problems visible as they are identified ✓ Contribute to increasing our or

  40. Slide 40: Robust Pipeline Driving Further Growth

    Confidential and subject to change Par Health Robust Pipeline in Sterile Injectables and Core Generics Driving Further Growth Road to Growth Strategy ✓ Following a Q4 2024 reassessment, the sterile injectables pipeline was streamlined to prioritize fewer, higher-impact assets – resulting in a more f

  41. Slide 41: Stable Margin Profile Drives Strong Free Cash Flow Generation

    Confidential and subject to change Par Health $306 $413 $425 2025E 2026E 2027E UFCF $56 $54 $55 $33 $41 $24 $89 $94 $79 2025E 2026E 2027E Maintenance CapEx Growth CapEx $499 $517 $511 2025E 2026E 2027E PF. Adj. EBITDA 1. Pre-Tax Unlevered Free Cash Flow calculated as PF. Adj. EBITDA (with $35mm of a

  42. Slide 42: Modest Leverage and Conservative Financial Policy

    Confidential and subject to change Par Health ▪ Primary focus on debt repayment in near-term following closing of the separation ▪ Retained excess free cash flow to be used for accretive reinvestment and shareholder distributions ▪ Financing Assumptions: • Debt Quantum: $1,350mm, consisting of a $20

  43. Slide 43: Financial Overview

    Confidential and subject to change Par Health Confidential and subject to change Financial Overview

  44. Slide 44: Financial Summary: 2022A – 2027E

    Confidential and subject to change Financial Summary: 2022A – 2027E Par Health 34 Revenue by Legacy Business Unit Revenue By Segment 1. Pipeline figures are risk adjusted Revenue (On Market vs. Pipeline1 ) Pipeline % $2,030 $1,857 $1,693 $1,730 $1,695 $1,614 $10 $65 $113 $2,030 $1,857 $1,693 $1,741

  45. Slide 45: Financial Summary: 2022A – 2027E (Cont'd)

    Confidential and subject to change Par Health $752 $495 $296 $306 $413 $425 2022A 2023A 2024A 2025E 2026E 2027E UFCF $1,014 $803 $696 $684 $689 $688 2022A 2023A 2024A 2025E 2026E 2027E Gross Profit Financial Summary: 2022A – 2027E (Cont’d) 35 Gross Profit PF. Adj. EBITDA1 Unlevered Free Cash Flow2 $

  46. Slide 46: Pro forma financial projections and credit metrics

    Confidential and subject to change Par Health At Close 2025E 2026E 2027E (LTM Q2'25) Revenue $1,646.4 $1,740.7 $1,760.5 $1,726.6 Growth % 2.8% 1.1% (1.9%) Gross Profit $620.5 $683.8 $689.2 $687.7 Margin % 37.7% 39.3% 39.1% 39.8% PF. Adj. EBITDA $422.8 $498.8 $517.4 $511.3 Margin % 25.7% 28.7% 29.4%

  47. Slide 47: Financial Policy and Capital Allocation Strategy

    Confidential and subject to change Financial Policy and Capital Allocation Strategy Par Health 37 Focus on Near-Term Deleveraging Shareholder Distributions Invest in the Business ▪ Meaningful deleveraging based off company’s sizeable free cash flow generation ▪ Maintain conservative financial profil

  48. Slide 48: Disclaimer

    Confidential and subject to change Disclaimer Par Health 38 This Investor Presentation (“presentation”) contains confidential information regarding the businesses of Endo, Inc. and its subsidiaries (collectively, “Endo”) and Mallinckrodt plc and its subsidiaries (collectively, “Mallinckrodt” and tog

  49. Slide 49: Par Health Combined Segment Adjusted EBITDA

    1 PAR HEALTH COMBINED SEGMENT ADJUSTED EBITDA (unaudited, in millions) Period Ending1 Specialty Generics Adjusted EBITDA2 GxSI Combined3 Adjusted EBITDA2 Pro forma adjustments4 Combined Pro Forma Par Health Adjusted EBITDA Trailing Twelve Month Pro Forma June 27, 2025 (Estimated) $ 254.4 $ 181.4 $ (

  50. Slide 50: Mallinckrodt Specialty Generics Segment Adjusted EBITDA

    2 MALLINCKRODT PLC SPECIALTY GENERICS SEGMENT ADJUSTED EBITDA (unaudited, in millions) Period Ending Specialty Generics Adjusted EBITDA 2 Trailing Twelve Month Pro Forma June 27, 2025 (Estimated) $ 254.4 Estimated Three Months Ended June 27, 2025 53.3 Three Months Ended March 28, 2025 67.2 Fiscal Ye

  51. Slide 51: Mallinckrodt Segment Operating Income to Adjusted EBITDA Reconciliations - Continued

    3 MALLINCKRODT PLC SEGMENT OPERATING INCOME TO ADJUSTED EBITDA RECONCILIATIONS - CONTINUED (unaudited, in millions) Predecessor Predecessor Non-GAAP Combined9 June 17, 2022 to December 30, 2022 January 1, 2022 to June 16, 2022 Fiscal Year Ended December 30, 2022 Specialty Generics Segment Operating

  52. Slide 52: Mallinckrodt Specialty Generics Segment Adjusted Gross Margin

    4 MALLINCKRODT PLC SPECIALTY GENERICS SEGMENT ADJUSTED GROSS MARGIN (unaudited, in millions) Period Ending Specialty Generics Adjusted Gross Margin Fiscal Year Ended December 27, 2024 $ 385.3 Fiscal Year Ended December 29, 2023 286.2 Fiscal Year Ended December 30, 2022 184.7 MALLINCKRODT PLC SEGMENT

  53. Slide 53: Mallinckrodt Specialty Generics Segment Unlevered Free Cash Flow

    5 MALLINCKRODT PLC SPECIALTY GENERICS SEGMENT UNLEVERED FREE CASH FLOW (unaudited, in millions) Period Ending Specialty Generics Unlevered Free Cash Flow Fiscal Year Ended December 27, 2024 $ 171.2 Fiscal Year Ended December 29, 2023 99.1 Fiscal Year Ended December 30, 2022 111.1 MALLINCKRODT PLC SE

  54. Slide 54: Endo GxSI Combined Segment Adjusted EBITDA

    6 ENDO, INC. GXSI COMBINED SEGMENT ADJUSTED EBITDA (unaudited, in millions) Period Ending GxSI Combined Segment Adjusted EBITDA 2 Trailing Twelve Month Pro Forma June 30, 2025 (Estimated) $ 181.4 Estimated Three Months Ended June 30, 2025 55.7 Three Months Ended March 30, 2025 19.8 Year Ended Decemb

  55. Slide 55: Endo Segment Operating Income to Adjusted EBITDA Reconciliations - Continued

    7 ENDO, INC. SEGMENT OPERATING INCOME TO ADJUSTED EBITDA RECONCILIATIONS - CONTINUED (unaudited, in millions) Predecessor Year Ended December 31, 2023 Year Ended December 31, 2022 GxSI Combined Segment Operating Income per SEC8 $ 395.0 $ 685.6 Adjustments: Acquired in-process research and developmen

  56. Slide 56: Endo GxSI Adjusted Gross Margin Reconciliations - Continued

    8 ENDO, INC. GXSI COMBINED SEGMENT ADJUSTED GROSS MARGIN RECONCILIATIONS - CONTINUED (unaudited, in millions) Predecessor Year ended December 31, 2023 Year ended December 31, 2022 GxSI Combined Segment Net Sales $ 1,079.9 $ 1,385.1 Less: GxSI Combined Cost of Sales (669.7) (720.7) Adjustments: Restr

  57. Slide 57: Endo GxSI Combined Segment Unlevered Free Cash Flow

    9 ENDO, INC. GXSI COMBINED SEGMENT UNLEVERED FREE CASH FLOW (unaudited, in millions) Period Ending GxSI Combined Segment Unlevered Free Cash Flow Year Ended December 31, 2024 $ 159.5 Year Ended December 31, 2023 430.7 Year Ended December 31, 2022 675.7 ENDO, INC. GXSI COMBINED SEGMENT UNLEVERED FREE

Mallinckrodt — Debt Investor Presentation (August 2025) on 6ix